Pooled analysis of 5y outcomes with pembrolizumab + chemotherapy in PD-L1 negative NSCLC JTO & JTO CRR. Includes KEYNOTE 189, 407, and extension studies. With 60.7m f/u, addition of pembro to chemo improves OS (HR 0.64) & PFS (HR 0.66). 5y OS rate 12.5%.

jto.org/article/S1556-…

#AACR24 While durable responses seen, overall outcomes similar to chemo-immunotherapy, both in terms of efficacy and safety. It remains challenging to interpret combinations without a proper control, though, particularly in #SCLC .

Results from KEYNOTE-B99 from Dr. Delvys Rodriguez Abreu at #AACR24 : phase II study in #SCLC of 1L pembrolizumab + EP + either MK-4830 (anti-ILT4), MK-5890 (boserolimab, CD27 agonist), or lenvatinib. RR 65-74% and mPFS 5.5-7.2 months.

A mechanism of action through which anti-TIGIT inhibitors can modify immunosuppressive tumor microenvironments - Ignacio Gil-Bazo
Delvys Rodriguez Abreu

#Cancer #NaturePublication #OncoDaily #Oncology #Cancer Care

oncodaily.com/38783.html

Martín Lázaro Martín Lázaro :
“Con la inmunoterapia, logramos largos supervivientes en tumores impensables”

elpais.com/salud-y-bienes…

Vía EL PAÍS

Nueva publicación del Registro de Tumores Torácicos (RTT) en Lung Cancer Elsevier
🔴Características clínicas e información genética de pacientes +80 años👨🏻‍🦳
🧬la proporción de pacientes mayores con mutaciones dirigidas es 🔼
+info: authors.elsevier.com/c/1ihTbcYZOf17D

Me ha encantado y yo volvería a hacer oncología médica. Enhorabuena César!!
I would definitely choose medical oncology again!!

Is there a predictive role for blood based #TMB and chemo-immunotherapy in NSCLC? KEYNOTE 782 results Lung Cancer Journal show that bTMB was NOT associated with PFS or OS for 1L platinum + pemetrexed + pembrolizumab in NSCLC. Jair Bar Delvys Rodriguez Abreu sponce

lungcancerjournal.info/article/S0169-…

Thanks again to Drs. Delvys Rodriguez Abreu charocampelo Luis Paz-Ares for a valuable and memorable #ITCD2024 in Gran Canaria. Loved the exchange of information and perspective among friends and colleagues! Fundación Canaria de Cáncer de Pulmón

Gracias al Ayuntamiento de Arucas y a su alcalde D. Juan Jesús Facundo por las jornadas #Cánceryvida en la que pudimos participar ayer.

Iniciativas como esta tienen un alto valor social.
Un orgullo haber estado.

#oncología #pacientes
#salud #bienestar #deporte

'The state of the art of EGFR exon 20 insertions in non-small cell #lungcancer : Diagnosis and future perspectives'.

✏️It's a paper written -among other doctors - by Dr. Delvys Rodríguez Abreu Delvys Rodriguez Abreu

You're welcome to access: authors.elsevier.com/c/1iVQt15X3~ab…

A big thanks to the amazing team Fundación Canaria de Cáncer de Pulmón, Delvys Rodriguez Abreu Luis Paz-Ares, attendees, and speakers!!! Great meeting, full of good science and friendship!!!! It couldn’t be done without all of you.

Today we closed #ITCD2024 after two succesful days.

We all made this dream came true again. We're really grateful to speakers, attendees, authorities and supporters for their commitment.

We looking forward to see you again!
#oncology #lungcancer

Dr. Dr. Antonio Calles 🫁🚭 expertly discusses targeting #HER2 in NSCLC at #ITCD2024 . Several different strategies with traztuzumab deruxtecan T-DXd the approved option. Emerging data with TKIs are very exciting including zongertinib - which seems to have a wide therapeutic window.

Time to wrap up two fantastic days full of science, debates and friendship. #ITCD2024 See you next year in Gran Canaria!! #lcsm

Time for outstanding discussions and time for meeting friends and colleagues #ITCD2024 An outstanding highly interactive meeting! Solange Peters Ben Solomon Stephen V Liu, MD Delvys Rodriguez Abreu Luis Paz-Ares

Dr. Lorenza Landi discusses #ALK NSCLC and how to strike balance between efficacy and safety in 1L. Lorlatinib is most potent but neurocognitive toxicity is the “dark side of this brilliant moon.” 🤩 Early recognition key and fortunately mostly low grade. #ITCD2024

👏➡️ Ha sido un placer participar hoy en la apertura del II International Lung Cancer Debate 2024 que reúne a más de un centenar de oncólogos internacionales en Las Palmas de Gran Canaria para debatir sobre los avances de esta especialidad.

📢 Inauguración de las Jornadas de Investigación Biomédica y Sanitaria de Canarias.

👥️ Acompañada por el rector de ULPGC Lluís Serra y la directora del Instituto Universitario de Investigaciones Biomédicas y Sanitarias Ana M Wägner.